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Abstract: The enantioselective synthesis (3.7% overall yield in nine steps from 2) and biological
screening of the ethyl analog of the macrocyclic marine alkaloid haliclorensin C (compound 5)
are reported. Amino alcohol 3, generated by a LiNH2BH3-promoted reductive ring-opening/
debenzylation sequence from phenylglycinol-derived lactam 2, was used as the starting chiral
linear building block. Incorporation of the undecene chain via the nosyl derivative 12, methylenation
of the pentanol moiety, and a ring-closing metathesis are the key steps of the synthesis.
Keywords: alkaloids; macrocycle; amino alcohols; ring opening; reduction; enantioselective synthesis
1. Introduction
Haliclorensin C (1) is a minor marine alkaloid isolated from the sponge Haliclona tulearensis
collected in January 2006 in Salary Bay, Madagascar [1]. From 86 g of a frozen wet sample
of sponge, only 2 mg (0.002 wt.%) of haliclorensin C (1) was isolated. The structure of 1 was
assigned as 3-methylazacyclohexadecane from its 1H- and 13C-NMR spectroscopic data, with the
aid of HMBC and COSY experiments, and mass spectrometry data (HREIMS). Based on biogenetic
considerations, the stereogenic center of haliclorensin C was tentatively proposed to possess the
S absolute configuration as previously determined for haliclorensin and halitulin, two related
azamacrocyclic alkaloids isolated from the same marine sponge [2,3]. Haliclorensin C exhibited
moderate toxicity in the brine shrimp (Artemia salina) test (LD50 value 2.1 mM) [1], whereas haliclorensin
and halitulin were shown to have significant cytotoxicity, the former against P-388 mouse leukemia
cells [4] and the latter against several tumor cell lines [5] (Figure 1).Molecules 2019, 24, x FOR PEER REVIEW 2 of 9 
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Lactam 2, bearing the required ethyl substituent with the appropriate stereochemistry, was 
efficiently converted (75% yield) to amino diol 7 [9] by treatment with lithium amidotrihydroborate 
(LiNH2BH3) [14,15] generated in situ by deprotonation of the commercially available borane-
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The proposed structure for haliclorensin C was confirmed in 2014 by total synthesis [6], although
comparison of the 1H- and 13C-NMR spectra of both the base and hydrochloride of the synthetic
product with the spectra reported for the natural product revealed that the isolated sample of
haliclorensin C corresponded to a protonated sample. From the stereochemical standpoint, the
synthesis relies on the use of a chiral amino alcohol building block (fragment N1-C6 of haliclorensin
C) generated from a phenylglycinol-derived oxazolopiperidone lactam that contains the required S
stereocenter at the β carbon to the amino group.
In recent years we have reported the preparation of enantiopure five-carbon linear building blocks
from phenylglycinol-derived bicyclic lactam scaffolds and their application to the enantioselective total
synthesis of macrocyclic natural products, such as haliclorensin marine alkaloids [6], fluvirucinin B1 [7],
and callyspongiolide [8]. Our approach involves the LiNH2BH3-promoted reductive opening of the
oxazolidine and lactam rings of the starting oxazolopiperidone lactam, and the subsequent reductive [9]
or oxidative [7] removal of the chiral inductor to give diversely substituted 5-aminopentanols [9],
5-hydroxypentanoic acids or 5-hydroxypentanenitriles [7]. Taking into account the availability
of starting lactams with a variety of substitution and stereochemical patterns [10,11], the above
methodology provides easy access to a range of useful functionalized chiral linear building blocks
with potential application in the enantioselective synthesis of natural product analogs.
2. Results and Discussion
We herein present the enantioselective synthesis of the ethyl analog of haliclorensin C
(compound 5) and the results of its in vitro screening in a panel of biological assays. Marine natural
products and their modified derivatives have long been recognized as one of the most important
sources of new biologically active substances and therapeutic agents [12,13].
The assembly of the azacyclohexadecane ring of 5 would be accomplished by a ring-closing
metathesis (RCM) reaction of an appropriate N-(hexenyl)undecenylamine 4 (bond formed C6-C7),
which would be prepared from amino alcohol 3, easily available from bicyclic lactam 2, by incorporation
of a C11 chain bearing a terminal double bond and subsequent methylenation of the pentanol moiety
(Scheme 1).
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Sche e 1. Synthetic strategy.
Lacta bearing the required ethyl substituent wi the appropriate ster ochemistry,
was efficiently conv rted (75% yield) to amino diol 7 [9] by treatment it li i roborate
(LiNH2B 3) [14,15] generated in situ by deprotonati of the commer ially available borane-ammonia
complex with n-BuLi. This transformation involves an initial hydride attack on the lactam carbonyl,
followed by a Grob-type fragmentation resulting in a double ring-opening by cleavage of the C–N and
C–O bonds, with a final hydride reduction of the resulting imino aldehyde intermediate. Unfortunately,
removal of the chiral inductor of 7 by hydrogenolysis, followed by silylation of the resulting crude
amino alcohol 3, afforded the primary amine 8 in low overall yield (Scheme 2). In a first approach to
compound 5, the undecene chain was introduced by reductive amination with 10-undecenal. Starting
from either the crude amino alcohol 3 or the O-protected derivative 8, the corresponding secondary
amines 9 or 10 were obtained, but also in low yield. For this reason, although the amino group of 9
was satisfactorily protected as the N-Boc derivative 11, this route was abandoned.
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by debenzylation of amino diol 7 by hydrogenolysis, followed by reaction of the res lti cr i
l l it - itr s lf l l ri ( ). l l ti st s rf r i t
r sence of Cs2CO3, leading to alcohol 13 in excellent yield (84%). A subsequent D ss-Martin oxidation,
followed by a Wittig methylenation of the resulti g aldehyde, afforded N-(hexenyl)undecenylamine 14
in 47% overall yield. Macrocyclization of di ne 14 took place satisfactorily by ring-closing metathesis
using the second-generation Grubbs catalyst in refluxing dichlor methane under dilute solve t
conditions, providing a 88:12 diastereois meric mixture of E/Z cycloalken s 15 in 70% yield. R moval
of the nosyl group by treatment with thiop nol, followed catalytic hydrogenation f the resulting
mixture of azamacrocyclic alk nes 16, afforded the ethyl an log of haloclorensin C (5).
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Compound 5 was submitted to biological screening in the context of the Lilly Open Innovation
Drug Discovery (OIDD) program, where it was subjected to a battery of assays against new
potential therapeutic targets. Among all the tests performed, the most pharmacologically relevant
results were obtained in the oncology area. Specifically, compound 5 caused 30% inhibition of
SETD8 at a concentration of 10 µM, measured through a scintillation proximity assay (SPA) of
enzyme inhibition [16]. SETD8 is a lysine methyltranferase that methylates histone H4 at Lys 20.
Its overactivation or overexpression has been found to play a role in the progression of certain cancers
such as neuroblastoma [17]. Accordingly, inhibition of SETD8 in neuroblastoma leads to increased p53
tumor suppressor activity and reduced tumor cell growth, resulting in prolonged survival in mouse
models of this neoplasia.
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On the other hand, compound 5 yielded a 10.2% inhibition of cyclin-dependent kinase 2 (CDK2)
at a concentration of 20 µM, measured through the SPA assay [18]. CDK2 is involved in cell cycle
progression, and thus has been indirectly linked to cancer through its association with cyclin E, which
activates it. Cyclin E binds to CDK2 to further phosphorylate the retinoblastoma proteins, which
repress the E2F transcription factors, thus releasing and fully activating the E2Fs. E2Fs then trigger
the transcription of S-phase proteins, including other cyclins, and promote cell cycle progression [19].
Cyclin E is frequently amplified in human tumors and is thought to promote proliferation and genome
instability in several cancers.
In conclusion, the results herein reported further demonstrate the usefulness and versatility of
chiral linear building blocks generated from phenylglycinol-derived oxazolopiperidone lactams in
the synthesis of bioactive natural products and analogs. Our synthesis also illustrates the potential of
ring-closing metathesis reactions for the efficient construction of azamacrocyclic rings [20–22]. In the
light of the reported structure-activity relationships and inhibitory data of some SETD8 inhibitors [23],
modifications of compound 5 could lead to a new series of SETD8 inhibitors with therapeutic potential.
Finally, although the low inhibition of CDK2 caused by compound 5 rules out a potential therapeutic
use based on this target, the possibility of a synergistic dual effect of this compound and its derivatives
on SETD8 and CDK2 remains to be investigated.
3. Materials and Methods
3.1. General Information
All air sensitive manipulations were carried out under a dry argon or nitrogen atmosphere.
THF and CH2Cl2 were dried using a column solvent purification system. Analytical thin-layer
chromatography was performed on SiO2 (silica gel 60A 35–70 µm, Carlo Erba, Val de Reuil Cedex,
France), and the spots were located with 1% aqueous KMnO4. Chromatography refers to flash
chromatography, and was carried out on SiO2 (SDS silica gel 60 ACC, 35–75 mm, 230–240 mesh
ASTM). Hydrogenations were carried out in a Parr 4560 high-pressure reactor. NMR spectra were
recorded at 300 or 400 MHz (1H) and 100.6 MHz (13C), and chemical shifts are reported in δ
values downfield from TMS, or relative to residual chloroform (7.26 ppm, 77.0 ppm) as an internal
standard (see Supplementary Materials). Data are reported in the following manner: chemical shift,
multiplicity, coupling constant (J) in hertz (Hz), integrated intensity, and assignment (when possible).
Assignments are given only when they are derived from definitive two-dimensional NMR experiments
(g-HSQC-COSY). IR spectra were performed in an Avatar 320 FT-IR spectrophotometer (Thermo
Nicolet, Madison, WI, USA) and only noteworthy IR absorptions (cm−1) are listed. High resolution
mass spectra (HMRS; LC/MSD TOF, Agilent Technologies, Santa Clara, CA, USA) were performed by
Centres Científics i Tecnològics de la Universitat de Barcelona.
3.2. Experimental Procedures
(S)-4-Ethyl-5-{[(1R)-2-hydroxy-1-phenylethyl]amino}-1-pentanol (7). n-BuLi (3.90 mL of a 2.5 M solution in
hexanes, 9.67 mmol) was added to a solution of the borane–ammonia complex (300 mg, 9.67 mmol) in
anhydrous THF (6 mL) at 0 ◦C, and the resulting mixture was stirred at this temperature for 10 min
and at room temperature for 15 min. This solution was added to a solution of lactam 2 [24] (550 mg,
2.25 mmol) in anhydrous THF (5 mL), and the stirring was continued at 40 ◦C for 1 h. The reaction
mixture was quenched with H2O, and the resulting solution was extracted with Et2O. The combined
organic extracts were dried over anhydrous Na2SO4 and filtered, and the solvent was removed under
reduced pressure. Flash chromatography (from 8:2 hexane-EtOAc to 8:2 EtOAc-EtOH) of the residue
gave amino diol 7 (425 mg, 75% yield) as a colorless oil: [α]22D −44.9 (c 0.16, MeOH); IR (ATR Pike)
ν (cm−1): 3330 (NH); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC): δ = 0.82 (t, J = 7.6 Hz, 3H, CH3),
1.23–1.40 (m, 3H, H-3, CH3CH2), 1.42–1.50 (m, 4H, H-2, H-3, H-4), 2.40 (dd, J = 11.6, 6.4 Hz, 1H, H-5),
2.46 (dd, J = 11.6, 5.0 Hz, 1H, H-5), 3.41 (br.s, 3H, OH, NH), 3.57–3.64 (m, 3H, H-1, CH2O), 3.71 (dd,
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J = 10.8, 4.0 Hz, 1H, CH2O), 3.77 (dd, J = 8.8, 4.0 Hz, 1H, CHN), 7.24–7.38 (m, 5H, ArH); 13C-NMR
(100.6 MHz, CDCl3): δ = 11.3 (CH3), 24.9 (CH3CH2), 27.4 (C-3), 29.2 (C-2), 38.8 (C-4), 50.2 (C-5), 60.3
(C-1), 64.8 (CHN), 66.5 (CH2O), 127.3 (CH-Ar), 127.6 (CH-Ar), 128.6 (CH-Ar), 139.9 (C-i); HRMS (ESI)
calcd for [C15H25NO2 + H+]: 252.1958, found. 252.1947.
(S)-5-[(tert-Butyldiphenylsilyl)oxy]-2-ethyl-1-pentanamine (8). A solution of aminodiol 7 (241 mg,
0.96 mmol) in anhydrous MeOH (10 mL) containing 20% Pd(OH)2 (48 mg) was hydrogenated at
75 ◦C for 18 h under 10 bar of pressure. The catalyst was removed by filtration and washed with hot
MeOH. The organic solution was concentrated, and the resulting crude amino alcohol 3 was dissolved
in CH2Cl2 (3 mL). Imidazole (271 mg, 3.98 mmol) and TBDPSCl (1.09 g, 3.98 mmol) were added,
and the mixture was stirred at room temperature for 12 h and at 40 ◦C for 4 h. Saturated aqueous
NH4Cl was added, and the mixture was extracted with CH2Cl2. The combined organic extracts were
dried over anhydrous MgSO4 and filtered, and the solvent was removed under reduced pressure.
Flash chromatography (from 95:5 hexane-EtOAc to EtOAc) of the residue gave amine 8 (115 mg, 32%
yield) as a yellow oil: [α]22D −5.78 (c 0.32, CHCl3); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC):
δ = 0.88 (t, J = 7.4 Hz, 3H, CH3CH2), 1.04 [s, 9H, (CH3)3], 1.32–1.44 (m, 2H, H-3, CH3CH2), 1.45–1.58 (m,
4H, H-3, H-4, CH3CH2), 1.68–1.77 (m, 1H, H-2), 2.79 (dd, J = 12.8, 7.8 Hz, 1H, H-1), 2.89 (dd, J = 12.8,
5.4 Hz, 1H, H-1), 3.64 (t, J = 7.4 Hz, 2H, H-5), 7.34–7.43 (m, 6H, ArH), 7.63–7.66 (m, 2H, ArH), 7.70–7.73
(m, 2H, HAR); 13C-NMR (100.6 MHz, CDCl3): δ = 10.2 (CH3CH2), 19.3 [C(CH3)3], 23.6 (CH2), 26.7
(CH2), 27.0 [C(CH3)3], 29.2 (C-4), 37.5 (C-2), 42.7 (C-1), 63.9 (C-5), 127.8 (CH-Ar), 127.8 (CH-Ar), 129.7
(CH-Ar), 129.7 (CH-Ar), 134.0 (C-Ar), 134.9 (CH-Ar), 135.4 (C-Ar), 135.7 (CH-Ar).
(S)-4-Ethyl-5-(10-undecenylamino)-1-pentanol (9). A solution of amino diol 7 (370 mg, 1.47 mmol) in
anhydrous MeOH (10 mL) containing 20% Pd(OH)2 (74 mg) was hydrogenated at 75 ◦C for 18 h
under 10 bar of pressure. The catalyst was removed by filtration and washed with hot MeOH. The
organic solution was concentrated, and the resulting crude amino alcohol 3 was dissolved in CH2Cl2
(1.3 mL). 10-Undecenal (0.58 mL, 2.94 mmol), NaBH3CN (277 mg, 4.42 mmol), and AcOH (0.13 mL)
were added, and the mixture was stirred at room temperature for 12 h. Then, a saturated solution of
NaHCO3 was added, and the mixture was extracted with CH2Cl2. The combined organic extracts were
dried over anhydrous Na2SO4 and filtered, and the solvent was removed under reduced pressure.
The residue was purified by flash chromatography (from 8:2 hexane-EtOAc to 8:2 EtOAc-MeOH) to
afford secondary amine 9 (104 mg, 25% yield) as a colorless oil: [α]22D −2.15 (c 0.3, MeOH); IR (ATR
Pike) ν (cm−1): 2926 (NH); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC): δ = 0.89 (t, J = 7.4 Hz, 3H,
CH3CH2), 1.21–1.69 (m, 21H, H-4, 10CH2), 1.99–2.05 (m, 2H, CH2=CHCH2), 2.56–2.61 (m, 1H, H-5),
2.66–2.75 (m, 3H, H-5, CH2N), 3.62 (m, 2H, H-1), 4.43 (br.s, 1H, NH), 4.89–5.00 (m, 2H, CH2=CH), 5.79
(dddd, J = 16.9, 10.2, 10.2, 6.7 Hz, 1H, CH2=CH); 13C-NMR (100.6 MHz, CDCl3): δ = 11.0 (CH3CH2),
24.9 (CH2), 27.1 (CH2), 27.1 (CH2), 28.3 (CH2), 28.6 (CH2), 28.9 (CH2), 29.1 (CH2), 29.3 (CH2), 29.3
(CH2), 29.5 (CH2), 33.8 (CH2=CHCH2), 37.7 (C-4), 49.5 (CH2N), 52.2 (C-5), 62.1 (C-1), 114.1 (CH2=CH),
139.1 (CH2=CH); HRMS (ESI) calcd for [C18H37NO + H+]: 284.2948, found: 284.2939.
(S)-5-[(tert-Butyldiphenylsilyl)oxy]-2-ethyl-N-(10-undecenyl)-1-pentanamine (10). 10-Undecenal (0.05 mL,
0.25 mmol) and AcOH (0.02 mL) were added to a suspension of amine 8 (74 mg, 0.20 mmol) and
NaBH3CN (25 mg, 0.40 mmol) in anhydrous CH2Cl2 (2.3 mL), and the mixture was stirred at
room temperature for 12 h. Then, water was added, and the mixture was extracted with CH2Cl2.
The combined organic extracts were dried over anhydrous Na2SO4 and filtered, and the solvent was
removed under reduced pressure. Flash chromatography (from 98:2 hexane-EtOAc to EtOAc) of the
residue gave secondary amine 10 (30 mg, 29% yield) as a colorless oil: [α]22D −12.3 (c 0.225, MeOH);
1H-NMR (400 MHz, CDCl3, COSY, g-HSQC): δ = 0.90 (t, J = 7.4 Hz, 3H, CH3CH2), 1.05 [s, 9H, (CH3)3],
1.24–1.58 (m, 18H, 9CH2), 1.65–1.77 (m, 3H, H-2, H-4), 2.01–2.06 (m, 2H, CH2=CHCH2), 2.81–2.84 (m,
2H, H-5), 2.88–2.96 (m, 2H, CH2N), 3.66–3.70 (m, 2H, H-1), 4.91–5.01 (m, 2H, CH2=CH), 5.80 (m, 1H,
CH2=CH), 7.32–7.55 (m, 6H, ArH), 7.63–7.67 (m, 4H, ArH); 13C-NMR (100.6 MHz, CDCl3): δ = 10.2
(CH3CH2), 19.3 [C(CH3)3], 23.1 (CH2), 23.7 (CH2), 25.8 (CH2), 26.7 (CH2), 26.8 (CH2), 27.0 [C(CH3)3],
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29.0 (CH2), 29.1 (CH2), 29.2 (CH2), 29.4 (CH2), 29.8 (CH2), 33.9 (CH2=CHCH2), 36.3 (C-4), 49.0 (CH2N),
51.6 (C-5), 63.8 (C-1), 114.3 (CH2=CH), 127.8 (CH-Ar), 129.8 (CH-Ar), 133.9 (C-Ar), 135.6 (CH-Ar), 139.3
(CH2=CH).
(S)-4-Ethyl-5-[N-(tert-butoxycarbonyl)-N-(10-undecenyl)amino]-1-pentanol (11). Et3N (0.04 mL, 0.28 mmol)
was added to a solution of 9 (82 mg, 0.29 mmol) and di-tert-butyl dicarbonate (69 mg, 0.32 mmol) in
anhydrous MeOH (1.5 mL), and the resulting solution was stirred for 12 h. Water was added, and the
mixture was extracted with CH2Cl2. The combined organic extracts were dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure. Flash chromatography (from 1:1 hexane-EtOAc
to EtOAc) of the residue gave the N-Boc derivative 11 (95 mg, 85% yield) as a colorless oil: [α]22D
–0.82 (c 0.6, MeOH); IR (ATR Pike) ν (cm−1): 3453 (OH); 1694 (CO); 1H-NMR (400 MHz, CDCl3,
COSY, g-HSQC): δ = 0.87 (t, J = 7.4 Hz, 3H, CH3CH2), 1.22–1.64 (m, 30H, C(CH3)3, H-4, 10CH2),
2.00–2.05 (m, 2H, CH2=CHCH2), 3.00–3.07 (m, 1H, H-5), 3.08–3.18 (m, 3H, H-5, CH2N), 3.54–3.64 (m,
2H, H-1), 4.89–5.00 (m, 2H, CH2=CH), 5.79 (dddd, J= 16.9, 10.2, 10.2, 6.7 Hz, 1H, CH2=CH); 13C-NMR
(100.6 MHz, CDCl3): δ = 10.8 (CH3CH2), 26.9 (CH2), 28.5 [C(CH3)3], 28.9 (CH2), 29.0 (CH2), 29.1 (CH2),
29.3 (2CH2), 29.4 (2CH2), 29.5 (CH2), 33.7 (CH2=CHCH2), 38.1 (C-4), 47.5 (CH2N), 50.3 (C-5), 63.1 (C-1),
79.1 [C(CH3)3], 114.0 (CH2=CH), 139.1 (CH2=CH), 156.0 (NCO); HRMS (ESI) calcd for [C23H45NO3 +
H+]: 384.3472, found: 384.3466.
(S)-4-Ethyl-5-[(2-nitrobenzenesulfonyl)amino]-1-pentanol (12). A solution of amino diol 7 (1.15 g,
4.58 mmol) in anhydrous MeOH (25 mL) containing 20% Pd(OH)2 (230 mg) was hydrogenated
at 75 ◦C for 18 h under 10 bar of pressure. The catalyst was removed by filtration and washed with hot
MeOH. The organic solution was concentrated, and the resulting crude amino alcohol 3 was dissolved
in anhydrous CH2Cl2 (16 mL). 2-Nitrobenzenesulfonyl chloride (1.12 g, 5.0 mmol) and Et3N (0.7 mL,
5.0 mmol) were added, and the mixture was stirred at room temperature for 18 h. The organic solvent
was removed under reduced pressure, and the residue was chromatographed (from 7:3 hexane-EtOAc
to EtOAc) to give N-nosyl derivative 12 (1.1 g, 76% yield) as a colorless oil: [α]22D +0.95 (c 0.84, MeOH);
IR (ATR Pike) ν (cm−1): 3348 (OH, NH); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC): δ = 0.84 (t,
J = 7.6 Hz, 3H, CH3), 1.30–1.40 (m, 4H, H-3, CH3CH2), 1.47–1.54 (m, 3H, H-2, H-4), 1.65 (br.s, 1H,
OH), 3.02 (dt, J = 6.1, 3.7 Hz, 2H, H-5), 3.60 (t, J = 6.4 Hz, 2H, H-1), 5.41 (t, J = 6.0 Hz, 1H, NH), 7.76
(m, 2H, H-5Ns, H-6Ns), 7.85 (m, 1H, H-4Ns), 8.13 (m, 1H, H-3Ns); 13C-NMR (100.6 MHz, CDCl3):
δ = 10.7 (CH3), 23.9 (CH3CH2), 26.9 (C-3), 29.3 (C-2), 33.1 (C-4), 46.2 (C-5), 62.8 (C-1), 125.3, 131.1
(C-3Ns, C-6Ns), 132.7 (C-4Ns), 133.5 (C-1Ns), 133.6 (C-5Ns), 148.0 (C-2Ns); HRMS (ESI) calcd for
[C13H20N2O5S + H+]: 317.1166, found: 317.1161.
(S)-4-Ethyl-5-[N-(2-nitrobenzenesulfonyl)-N-(10-undecenyl)amino]-1-pentanol (13). 11-Bromo-1-undecene
(0.80 mL, 3.65 mmol) was added to a suspension of N-nosyl derivative 12 (1.05 g, 3.3 mmol) and
Cs2CO3 (1.3 g, 4.0 mmol) in anhydrous DMF (25 mL), and the resulting mixture was stirred at 55 ◦C
for 3 h. The mixture was cooled to room temperature, poured into brine, and extracted with Et2O.
The combined organic extracts were dried over anhydrous MgSO4, filtered, and concentrated under
reduced pressure. Flash chromatography (7:3 hexane-EtOAc) of the residue gave alkene 13 (1.30 g,
84% yield) as a colorless oil: [α]22D +1.82 (c 0.7, CH2Cl2); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC):
δ = 0.85 (t, J = 7.6 Hz, 3H, CH3), 1.19–1.37 (m, 16H, 8CH2), 1.40–1.65 (m, 5H, H-4, CH2, CH3CH2),
2.02 (m, 2H, CH2=CHCH2), 3.19–3.25 (m, 4H, H-5, CH2N), 3.57 (t, J = 6.8 Hz, 2H, H-1), 4.95 (m, 2H,
CH2=CH), 5.80 (m, 1H, CH2=CH), 7.62 (m, 1H, H-4Ns), 7.67 (m, 2H, C-5Ns, C-6Ns), 7.98 (m, 1H,
H-3Ns); 13C-NMR (100.6 MHz, CDCl3): δ = 10.4 (CH3), 23.2 (CH2), 26.3 (CH2), 26.6 (CH2), 27.6 (CH2),
28.8 (CH2), 29.0 (CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 33.6 (CH2=CHCH2), 36.5 (C-4),
47.1 (CH2N), 50.7 (C-5), 62.8 (C-1), 114.0 (CH2=CH), 123.3 (C-3Ns), 130.6 (C-6Ns), 131.4 (C-4Ns), 133.3
(C-5Ns), 133.4 (C-1Ns), 139.0 (CH2=CH), 148.0 (C-2Ns); HRMS (ESI) calcd for [C24H40N2O5S + H+]:
469.2731, found: 469.2731.
Molecules 2019, 24, 1069 7 of 9
(S)-N-[2-Ethyl-5-hexenyl)-N-(2-nitrobenzenesulfonyl)-10-undecenamine (14). Dess–Martin reagent (2.35
g, 5.54 mmol) was added to a solution of alcohol 13 (1.3 g, 2.77 mmol) in anhydrous CH2Cl2 (21
mL), and the mixture was stirred at room temperature for 1.5 h. Then, saturated aqueous Na2S2O4
(0.75 mL) and saturated aqueous NaHCO3 (0.75 mL) were added, and the resulting mixture was
stirred for 1 h. The aqueous layer was extracted with CH2Cl2, and the combined organic extracts were
washed with brine, dried over anhydrous Na2SO4, and filtered. The solvent was evaporated to give an
aldehyde, which was used in the next step without further purification. t-BuOK (13.8 mL of a 1 M
solution in THF, 13.8 mmol) was added to a solution of methyltriphenylphosphonium bromide (6.92
g, 19.4 mmol) in anhydrous THF (70 mL), and the solution was stirred at room temperature for 1 h.
Then, a solution of the above aldehyde in anhydrous THF (10 mL) was added via cannula, and the
resulting mixture was stirred at room temperature for 3 h. Saturated aqueous NH4Cl was added, and
the mixture was extracted with EtOAc. The combined organic extracts were dried over anhydrous
Na2SO4 and filtered, and the solvent was removed under reduced pressure. Flash chromatography (9:1
hexane-EtOAc) of the residue gave diene 14 (600 mg, 47% yield) as a colorless oil: [α]22D +4.09 (c 2.1,
MeOH); 1H-NMR (400 MHz, CDCl3, COSY, g-HSQC): δ = 0.84 (t, J = 7.5 Hz, 3H, CH3), 1.14–1.39 (m,
16H, 8CH2), 1.41–1.49 (m, 2H, CH2), 1.54–1.64 (m, 1H, CH), 1.95–2.10 (m, 4H, CH2=CHCH2), 3.14–3.26
(m,4H, 2CH2N), 4.91–5.02 (m, 4H, CH2=CHCH2), 5.74 (qt, J = 16.9, 10.0, 6.7, 6.7 Hz, 1H, CH2=CH),
5.80 (qt, J = 16.9, 10.1, 6.7, 6.7 Hz, 1H, CH2=CH), 7.59–7.62 (m, 1H, H-3Ns), 7.63–7.70 (m, 2H, H-5Ns,
H-6Ns), 7.99–8.03 (m, 1H, H-4Ns). 13C-NMR (100.6 MHz, CDCl3): δ 10.3 (CH3), 23.2 (CH2), 26.6 (CH2),
27.5 (CH2), 28.9 (CH2), 29.0 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 30.6 (CH2=CHCH2),
33.8 (CH2=CHCH2), 36.0 (CH), 47.0 (CH2N), 50.7 (CH2N), 114.1 (CH2=CH), 114.7 (CH2=CH), 124.1
(C-3Ns), 130.9 (C-6Ns), 131.4 (C-4Ns), 133.2 (C-5Ns), 133.9 (C-1Ns), 138.5 (CH2=CH), 139.1 (CH2=CH),
148.0 (C-2Ns); HRMS (ESI) calcd for [C25H40N2O4S + H+]: 465.2782, found 465.2776.
(S)-3-Ethyl-1-(2-nitrobenzenesulfonyl)azacyclohexadec-6-ene (15). A solution of diene 14 (70 mg, 0.15
mmol) in anhydrous CH2Cl2 (15 mL) was added to a solution of second-generation Grubbs catalyst
(19 mg, 0.022 mmol) in CH2Cl2 (750 mL). The mixture was stirred at reflux temperature for 14 h.
The solvent was removed under reduced pressure, and the resulting residue was chromatographed
(95:5 hexane-EtOAc) to yield macrocycle 15 (46 mg, 70% yield) as a 88:12 mixture (calculated by
GC/MS) of E/Z diastereoisomers. Spectroscopic data of E diastereoisomer (from a mixture): 1H-NMR
(400 MHz, CDCl3, COSY, g-HSQC): δ = 0.83 (t, J = 7.5 Hz, 3H, CH3), 1.00–1.11 (m, 1H, H-4), 1.18–1.44
(m, 17H, H-4, 8CH2), 1.46–1.51 (m, 2H, CH2), 1.67–1.80 (m, 1H, H-3), 1.97–2.19 (m, 4H, H-5, H-8),
3.07 (dd, J = 13.8, 7.5 Hz, H-2), 3.11–3.15 (m, 1H, H-16), 3.21–3.26 (m, 1H, H-16), 3.28 (dd, J = 13.8,
7.5 Hz, H-2), 5.25–5.41 (m, 2H, H-6, H-7), 7.57–7.62 (m, 1H, H-3Ns), 7.63–7.73 (m, 2H, H-5Ns, H-6Ns),
7.93–8.04 (m, 1H, H-4Ns); 13C-NMR (100.6 MHz, CDCl3): δ = 9.6 (CH3), 21.9 (CH2), 24.3 (CH2), 25.7
(CH2), 26.1 (CH2), 26.1 (CH2), 26.7 (CH2), 26.7 (CH2), 27.3 (CH2), 28.8 (CH2=CHCH2), 29.6 (CH2), 30.9
(CH2=CHCH2), 33.3 (C-3), 46.7 (C-16), 51.3 (C-2), 124.0 (C-3Ns), 130.2 (CH=), 130.7 (C-6Ns), 131.3
(C-4Ns), 131.4 (C-5Ns), 133.2 (CH=), 133.4 (C-1Ns), 148.1 (C-2Ns); HRMS (ESI) calcd for [C23H36N2O4S
+ H+]: 437.2469, found 437.2459.
(S)-3-Ethylazacyclohexadec-6-ene (16). Thiophenol (0.024 mL, 0.34 mmol) and K2CO3 (82 mg, 0.59 mmol)
were added to a solution of cycloalkene 15 (86 mg, 0.20 mmol) in anhydrous DMF (4 mL), and the
mixture was stirred at room temperature for 14 h. Then, 2 M aqueous NaOH was added, and the
mixture was extracted with CH2Cl2. The combined organic extracts were dried over anhydrous MgSO4,
filtered, and concentrated under reduced pressure. Flash chromatography (from 95:5 hexane-EtOAc
to 8:2 EtOAc-Et3N) of the residue gave macrocycle 16 (23 mg, 45% yield) as a mixture of E/Z
diastereoisomers as a brown oil. Spectroscopic data of E diastereoisomer (from a mixture): 1H-NMR
(400 MHz, CDCl3, COSY, g-HSQC): δ = 0.87 (t, J = 7.5 Hz, 3H, CH3), 1.25–1.44 (m, 16H, 8CH2), 1.47–1.56
(m, 3H, CH2), 1.94–2.12 (m, 4H, H-5, H-8), 2.41 (dd, J = 12.1, 7.5 Hz, 1H, H-2), 2.51–2.57 (dd, J = 12.0,
6.4 Hz, 1H, H-16), 2.52–2.58 (dd, J = 12.1, 5.9 Hz, 1H, H-2), 2.62–2.68 (dd, J = 12.0, 5.7 Hz, 1H, H-16),
5.36–5.39 (m, 2H, H-6, H-7); 13C-NMR (100.6 MHz, CDCl3): δ = 10.8 (CH3), 24.4 (CH2), 25.2 (CH2),
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26.2 (CH2), 26.3 (CH2), 27.2 (CH2), 27.3 (CH2), 28.0 (CH2), 28.2 (CH2), 29.1 (CH2=CHCH2), 30.8 (CH2),
31.8 (CH2=CHCH2), 36.9 (C-3), 47.6 (C-16), 52.3 (C-2), 130.8 (CH=), 130.9 (CH=); HRMS (ESI) calcd for
[C17H33N + H+]: 252.2686, found 252.2689.
(S)-3-Ethylazacyclohexadecane (5). A solution of cycloalkene 16 (19 mg, 0.076 mmol) in anhydrous MeOH
(10 mL) containing 25% Pd/C (5 mg) was hydrogenated at room temperature for 14 h under 10 bar of
pressure. The catalyst was removed by filtration and washed with hot MeOH, and the organic solution
was concentrated under reduced pressure. Flash chromatography (from 95:5 hexane-EtOAc to 8:2
EtOAc-Et3N) of the residue gave 5 (10 mg, 52% yield) as a brown oil: [α]22D −6.75 (c 0.15, MeOH);
1H-NMR (300 MHz, CDCl3): δ = 0.90 (t, J = 7.5 Hz, 3H, CH3), 1.25–1.41 (m, 24H, 12CH2), 1.50–1.70
(m, 3H, H-3, CH2), 2.40 (m, 2H, H-2), 2.60–2.85 (m, 2H, H-16); 13C-NMR (100.6 MHz, CDCl3): δ = 10.8
(CH3), 24.8 (CH2), 24.9 (CH2), 25.0 (CH2), 26.0 (CH2), 26.1 (CH2), 26.2 (CH2), 26.3 (CH2), 26.4 (CH2),
26.5 (CH2), 27.1 (CH2), 27.4 (CH2), 29.7 (CH2), 29.8 (CH2), 35.6 (C-3), 46.1 (C-16), 49.1 (C-2); HRMS
(ESI) calcd for [C17H35N + H+]: 254.2842, found 254.2842.
Supplementary Materials: The following are available online, Copies of 1H and 13C NMR spectra.
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